W80. Hepatology 101 for ID Clinicians
Session: Premeeting Workshop: Hepatitis C Workshop
Wednesday, October 3, 2018: 10:35 AM
Room: S 156
Eliot Godofsky, MD, FIDSA, Bach and Godofsky, Bradenton, FL

Dr. Eliot Godofsky is a native New Yorker currently practicing in Bradenton, Florida since 1994. Dr. Godofsky graduated Cum Laude from Georgetown University School of Medicine in 1987, and completed his Internal Medicine internship and residency at The New York Hospital/ Cornell Medical Center in New York in 1990. From 1990 – 1992 Dr. Godofsky was a fellow in infectious disease at the Johns Hopkins Hospital in Baltimore, Maryland mentoring under Dr. John G. Bartlett. Following his ID fellowship, Dr. Godofsky practiced for a short time at Hershey Medical Center in Pennsylvania, before settling in private practice and clinical research as CEO of Bach & Godofsky, MD, PA in Bradenton, Florida. The practice currently consists of 6 physicians, over 30 employees, and is involved in ID consultation, outpatient antibiotic therapy, wound care, HIV care, Hepatitis C care, and clinical research. Dr. Godofsky also serves as the medical director of the wound care center at Bach & Godofsky, a private facility that services over 100 patients daily. Dr. Godofsky’s particular area of interest is in new drug development for HIV and chronic viral hepatitis. Dr. Godofsky has been a principal investigator in nearly 100 FDA clinical trials, published or presented over 50 scientific papers, and lectures extensively on his fields of research and patient management. Dr. Godofsky has served on the Program Committee, the Clinical Affairs Committee, the Standards and Practice Guidelines Committee, and the Research Committee (current) of the IDSA. Dr Godofsky is the current co-chairman of the annual IDSA fellows conference and a founding member of the IDSA Hepatitis C Task Force.


Disclosures:

E. Godofsky, None

See more of: Hepatitis C Workshop
See more of: Premeeting Workshop

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.